Use of Prior Information to Stabilize a Population Data Analysis

被引:0
作者
Per O. Gisleskog
Mats O. Karlsson
Stuart L. Beal
机构
[1] Exprimo Consulting LLP,Department of Pharmaceutical Biosciences
[2] Uppsala University,Department of Laboratory Medicine
[3] UCSF,undefined
来源
Journal of Pharmacokinetics and Pharmacodynamics | 2002年 / 29卷
关键词
prior information; Bayesian prior; frequentist prior; population analysis;
D O I
暂无
中图分类号
学科分类号
摘要
When modeling new data with a complex population pharmacokinetic/pharmacodynamic model, there may not be sufficient information to obtain estimates of all parameters. In this case information from previous studies can also be used to help stabilize estimation. Using simulated data, we explored three different ways to do this. (i) Some parameter values were fixed to estimates obtained from earlier data. (ii) The earlier data were combined with the current data. (iii) The objective function based on the current data was augmented by a penalty function expressing summary information obtained from the earlier data. This last method is similar to the use of a Bayesian prior. It may be particularly useful when either the combined data set of method (ii) is very large and leads to large computation times or when the early data are not readily available. With this method, two different types of penalty functions were used. With our examples, the three methods all resulted in stabilized estimation. Methods (ii) and (iii) gave similar results for parameter and standard error estimation, especially with respect to fixed effects parameters. For hypothesis testing, results obtained with method (i) are very problematic. There are also problems with the results obtained with method (iii), but they are much less severe, and when the design for the earlier data is known, they can be corrected by using a computer-intensive simulation test procedure.
引用
收藏
页码:473 / 505
页数:32
相关论文
共 44 条
  • [1] Yuh L.(1994)Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography Biometrics 50 566-575
  • [2] Beal S. L.(1994)Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis J. Pharmacokin. Biopharmaceutics 22 165-177
  • [3] Davidian M.(1993)Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis J. Pharmacokin. Biopharm. 21 209-222
  • [4] Harrison F.(1996)A population pharmacokinetic model for docetaxel (taxotere): Model building and validation J. Pharmacokin. Biopharm. 24 153-712
  • [5] Hestor A.(2000)Haematological toxicity following different dosing schedules of 5-fluorouacil and epirubicin in rats Anticancer Research 20 1519-1525
  • [6] Kowalski K.(1991)Application of population analysis to physiological pharmacokinetics J. Pharmacokin. Biopharm. 19 101S-113S
  • [7] Vonesh E.(1996)Physiological pharmacokinetic analysis using population modeling and informative prior distributions J. Am. Stat. Assn. 91 1400-1412
  • [8] Wolfinger R.(1996)The Bayesian analysis of population pharmacokinetic models J. of the American Statistical Association 91 62-75
  • [9] Wade J. R.(1994)Bayesian analysis of linear and nonlinear population models using the Gibbs sampler Appl. Stat. 43 201-222
  • [10] Beal S. L.(2001)Assessment of significance Levels for covariate effects in NONMEM J. Pharmacokin. Pharmacodyn. 28 231-252